ATFX adds Merck & Co share CFDs to its offering

Global broker ATFX announced adding new Merck & Co share CFDs to its trading platform in support of its ongoing commitment to offering a broad range of trading instruments to its clients.

Research-intensive biopharmaceutical company Merck works on preventing and treating diseases which threaten people, as well as animals such as cancer, HIV, Ebola and emerging animal diseases.

Merck has been operating for over 125 years and has brought to the market medicines and vaccines for many of the world’s most challenging diseases.

For the second quarter of 2020, the company reported strength in its stock with earnings increase of 5% to $1.50 per share, surpassing Wall Street expectations.

Merck’s sales for last year rose 11% to $46.82 billion accomplishing the best annual revenue for the company since 2010. For the fourth quarter of 2020, experts forecast sales to growth of 2.05% to $47.8 billion. Income is expected to increase 9.6% to $5.69 a share.

The company has received FDA approval for 63 new molecular entities as of 2014. Some of Merck’s leading drugs are Januvia, which treats type 2 diabetes and registered $4.0 billion in global sales and Zetia, a dietary cholesterol inhibitor, which had $2.7 billion in sales.

Currently, Merch is closely working with biotech Ridgeback Bio to develop an experimental antiviral approach to Covid-19 treatment.

ATFX has launched Marck & Co as a CFD, allowing investors to trade fractions of stocks rather than being forced to buy the whole. Even though CFDs have benefits, they also come with significant risk due to being leveraged products.

Source: https://www.leaprate.com/forex/brokers/atfx-adds-merck-co-share-cfds-to-its-offering

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.12% of retail investor accounts lose money when trading CFDs / Spread betting with this provider. You should consider whether you understand how CFDs / Spread betting work and whether you can afford to take the high risk of losing your money.

ATFX is a co-brand shared by a group entities including:

• AT Global Markets (UK) Ltd is authorized and regulated by the Financial Conduct Authority (FCA) in the United Kingdom with registration number 760555. The Registered Office: 1st Floor, 32 Cornhill, London EC3V 3SG, United Kingdom.
• AT Global Markets LLC is a Limited Liability Company in Saint Vincent and the Grenadines with company number 333 LLC 2020. The Registered Office: 1st Floor, First St. Vincent Bank Bldg, James Street, Kingstown, St. Vincent and the Grenadines.
• ATFX Global Markets (CY) Ltd is authorized and regulated by the Cyprus Securities and Exchange Commission (CySEC) under the license no. 285/15. The Registered Office: 159 Leontiou A' Street, Maryvonne Building Office 204, 3022, Limassol, Cyprus.
• AT Global Markets Intl Ltd is authorized and regulated by the Financial Services Commission with license Number C118023331. The Registered Office: Suite 207, 2nd Floor, The Catalyst, Silicon Avenue, 40 Cybercity, 72201 Ebène, Republic of Mauritius.